Project Grant W81XWH1010005

Federal Project Grant Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded $683,885 to The University of Texas Southwestern Medical Center on May 1, 2026, for a five-year project concluding April 30, 2031. The award funds the development of the first clinical prototype for proton minibeam radiation therapy (PMBRT), an advanced spatially fractionated radiation therapy modality designed to improve upon conventional radiation therapy by delivering a highly...

The National Cancer Institute (NCI) awarded a $1,003,173 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Radiopharmaceutical Imaging And Dosimetry, LLC, a company based in Baltimore, Maryland. The funding supports the development of a prototype web/cloud-based quantitative SPECT reconstruction software system for use in clinical trials and ultimately clinical dosimetry for radiopharmaceutical therapy (RPT). The software aims to enable accurate quantitative imaging...

Federal Grant Award Summary William Beaumont Hospital received a $498,372 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop a novel multi-approach dynamic Spot Scanning Proton Arc (SPARC) optimization framework. Awarded on September 1, 2025, with completion targeted for August 31, 2029, this project addresses critical clinical challenges in proton therapy delivery for cancer patients, particularly those with head and neck...

Federal Project Grant Award Summary Emory University received a $158,899 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded June 20, 2025, with completion targeted for May 31, 2027. This award supports the development of an innovative Simultaneous Intensity Energy Modulation and Compensation (SIEMAC) optimization platform and integrated quality assurance (QA) system for conformal flash proton therapy treatment of central lung...

Federal Cooperative Agreement Summary Radiabeam Technologies, LLC received a $1,079,989 Cooperative Agreement award from the Advanced Research Projects Agency - Energy (ARPA-E, CFDA 81.135) under the Nuclear Energy Waste Transmutation Optimized Now (NEWTON) funding opportunity. The award, issued on February 19, 2026, with a completion date of February 18, 2029, funds the development of a Niobium-Tin (Nb₃Sn) proton driver linear accelerator (linac) for accelerator-driven systems designed to...

Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research (award date: August 1, 2025; completion date: July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance radiotherapy efficacy through antigen-specific radiosensitization. The research focuses on delivering potent DNA damage...

The National Cancer Institute (NCI) awarded a $406,217 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Texas Health Science Center at Houston (UTHealth) to investigate the circadian regulation of astrocytic adenosine kinase (ADK) in the irradiated and cancer brain. The research aims to determine the impact of the circadian clock proteins BMAL1 and CLOCK on ADK expression and sleep/wake regulation following cranial radiotherapy (CRT) for brain cancers. The project...

Grant Award Summary The University of Pennsylvania received a $695,205 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct early-phase clinical trials of 211-astatine-meta-astatobenzylguanidine (211At-MABG) for treating neuroblastoma in children and advanced neuroendocrine cancers in adults. The award period runs from June 1, 2025, through May 31, 2030. The research addresses limitations of existing treatments,...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $414,402 Project Grant to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) for the period May 1, 2026 through April 30, 2028. This research project develops multi-modality imaging and biomarker integration methods to improve glioblastoma radiation therapy targeting. The deliverables include: (1) white matter infiltrative risk maps derived from diffusion...

This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...